Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
| ophthalmologic_monitoring_management_raf_mek_pathway_inhibitors [2026/07/01 22:36] – Scott Larson | ophthalmologic_monitoring_management_raf_mek_pathway_inhibitors [2026/07/01 22:38] (current) – [Ophthalmologic Monitoring and Management for RAF/MEK Pathway Inhibitors] Scott Larson | ||
|---|---|---|---|
| Line 1: | Line 1: | ||
| ====== Ophthalmologic Monitoring and Management for RAF/MEK Pathway Inhibitors ====== | ====== Ophthalmologic Monitoring and Management for RAF/MEK Pathway Inhibitors ====== | ||
| - | Here is a comprehensive overview of recommended ophthalmologic monitoring protocols and management strategies for patients on RAF/MEK pathway inhibitors, applicable to tovorafenib and its drug class. | + | Here is a comprehensive overview of recommended ophthalmologic monitoring protocols and management strategies for patients on [[mapk_pathway_drugs_ocular_toxicity|RAF/MEK pathway inhibitors]], applicable to tovorafenib and its drug class. |
| ===== Baseline Ophthalmologic Assessment ===== | ===== Baseline Ophthalmologic Assessment ===== | ||